Literature DB >> 23802855

Secondary prophylaxis vs. on-demand treatment to improve quality of life in severe adult haemophilia A patients: a prospective study in a single centre.

J A Aznar1, M García-Dasí, S Pérez-Alenda, A Marco, M Jaca, A Moret, F Querol.   

Abstract

BACKGROUND: Retrospective publications show a decrease in the bleeding frequency and an improvement in the quality of life (QoL) in severe adult haemophilia A (SAHA) after switching from the on-demand treatment (DT) to secondary prophylaxis (SP). But there are no prospective studies which demonstrate, using a haemophilia-specific questionnaire, an improvement in the QoL after such treatment change. The main objective of this study is to prospectively compare the QoL and the musculoskeletal assessment after switching from DT to SP in SAHA using the A36 Hemofilia-QoL(®) . As secondary objective, we compare the haemarthrosis frequency and factor VIII consumption in DT and SP during a similar period of time (12 months) after switching.
MATERIALS AND METHODS: We have designed a prospective study including SAHA who have been under DT and were changed to a protocol, which combines SP (biweekly administration of factor VIII) with individualized physiotherapy programme.
RESULTS: Twelve months after switching to SP, the QoL was significantly improved (P = 0·005). Musculoskeletal assessment of pathologic irreversible joints and joints with a reversible alteration was generally improved, although in only a few joints, this improvement was statistically significant. Haemarthrosis was strongly reduced (12·60-1·42, P < 0·001).
CONCLUSIONS: This prospective study has demonstrated a statistically significant improvement in the QoL after 1 year from switching patients from DT to SP. The musculoskeletal assessment after 1 year was maintained similar or slightly improved. When we compared retrospective DT and prospective SP, haemarthrosis where strongly reduced requiring a slight increase in the consumption of factor VIII concentrates.
© 2013 International Society of Blood Transfusion.

Entities:  

Keywords:  bleeding incidence; haemophilia A; musculoskeletal; quality of life; secondary prophylaxis

Mesh:

Substances:

Year:  2013        PMID: 23802855     DOI: 10.1111/vox.12066

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  3 in total

1.  Physical activity improved by adherence to prophylaxis in an Italian population of children, adolescents and adults with severe haemophilia A: the SHAPE Study.

Authors:  Ezio Zanon; Annarita Tagliaferri; Samantha Pasca; Cosimo P Ettorre; Lucia D Notarangelo; Chiara Biasioli; Anna B Aru; Marta Milan; Silvia Linari; Angiola Rocino; Fabio Gagliano; Giovanni Di Minno; Gabriella Gamba; Rita C Santoro; Piercarla Schinco; Marco Marietta; Axel Seuser; Sylvia von Mackensen
Journal:  Blood Transfus       Date:  2019-06-05       Impact factor: 3.443

2.  Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II).

Authors:  K Kavakli; R Yang; L Rusen; H Beckmann; D Tseneklidou-Stoeter; M Maas Enriquez
Journal:  J Thromb Haemost       Date:  2015-03       Impact factor: 5.824

3.  Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis.

Authors:  Maria Elisa Mancuso; Mark T Reding; Claude Negrier; Bryce A Kerlin; Savita Rangarajan; Mindy L Simpson
Journal:  Thromb Haemost       Date:  2020-12-09       Impact factor: 6.681

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.